Facebook Linkedin Twitter
Inside Precision Medicine Eisai and BMS End ADC Deal, But Eisai Will Continue Development

Bristol-Myers Squibb

3D Rendering of Antibody Drug Conjugate Molecules
News & Features

Eisai and BMS End ADC Deal, But Eisai Will Continue Development

0
Schizophrenia, conceptual image
News & Features

BMS Strengthens Schizophrenia, AD Portfolio with $14B Acquisition of Karuna Therapeutics

0
3D Rendering of Antibody Drug Conjugate Molecules
News & Features

BMS Pays $100M Upfront for Antibody Degrader Conjugate from Orum

0
cancer
News & Features

BMS Acquires KRAS Targeter Mirati in $4.8B Deal

0
Rapamycin inhibiting protein kinase mTORC1
News & Features

Astellas and PeptiDream Ink $21M Plus Protein Degrader Deal 

0
Acute lymphoblastic leukemia ALL-L2 blood smear under light microscopy
News & Features

$1.7B Merger of Sobi with Blood Cancer Specialist CTI BioPharma

0
3D Rendering of Antibody Drug Conjugate Molecules
News & Features

BMS and Tubulis Ink Potential $1B+ Deal around ADCs

0
Acute lymphoblastic leukemia ALL-L2 blood smear under light microscopy
News & Features

Test Predicts Likelihood of Revlimid Response in Myeloma

0
Micrograph of multiple myeloma neoplasm from bone marrow biopsy
News & Features

Earlier CAR T Therapy May Benefit Multiple Myeloma Patients

0
psoriasis on a middle aged man's elbow
News & Features

BMS Wins First-in-Class Psoriasis Approval with Deucravacitinib

0
1234Page 1 of 4

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine